Jeffrey Um Cohen

US Patent:

20080279886, Nov 13, 2008

Filed:

Jun 22, 2005

Appl. No.:

11/630147

Inventors:

Jeffrey I. Cohen - Silver Spring MD, US
Lesley M. Pesnicak - Stafford VA, US

Assignee:

The Govt. of the U.S.A. as represented by the Secretary, Dept. of Health and Human Services - Rockville MD

International Classification:

A61K 39/12
A61K 39/245
A61K 39/255
A61P 37/04
A61P 31/12
A61K 39/25
A61K 39/205

US Classification:

4241991, 4242041, 4242301, 4242311, 4242241

Abstract:

Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the varicella zoster virus. Deletion of a significant portion from both copies of the varicella zoster gene ORF63 was shown to inhibit establishment of a latent infection from a live vaccine form of the virus. Insertion of an additional ORF62 gene which is partially truncated with the ORF63 deletion inhibited establishment of latency and allowed normal growth of the virus. Other desirable viral antigen encoding sequence(s) and/or cytokine genes advantageously may replace deleted genetic material to enhance a desired immunological response. Aspects of the discovery pertain to live vaccines of other viruses, and can provide a variety of vaccines having greater safety.

US Patent:

20130209506, Aug 15, 2013

Filed:

Nov 9, 2007

Appl. No.:

12/514011

Inventors:

Jeffrey I. Cohen - Silver Spring MD, US
Lesley Pesnicak - Stafford VA, US

Assignee:

THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the secretary of the department of - Rockville MD

International Classification:

A61K 39/25

US Classification:

4241991, 4352351, 435236

Abstract:

The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.

US Patent:

49512781, Aug 21, 1990

Filed:

Aug 31, 1988

Appl. No.:

7/238581

Inventors:

Jeffrey Biber - Sterling VA
Jeffrey Cohen - Silver Spring MD
John Holmbald - Oakton VA
Douglas Kay - Chevy Case MD
Roy Spitzer - Vienna VA

Assignee:

Telenet Communications Corporation - Reston VA

International Classification:

H04L 1100

US Classification:

370 60

Abstract:

A data communications system has a layered communication architecture including network services protocols including a link layer and higher level protocols, and has IBM or IBM-compatible synchronous data link control (SDLC) devices including a host computer and a plurality of end user devices desiring to communicate across an X. 25 packet-switching network (PSN) of the communications system. A packet assembler/disassembler (PAD) support X. 25 communication across the PSN between the SDLC-utilizing host computer and the SDLC-utilizing end user device. In one embodiment, separate high level data link control (HDLC) PADs are provided at each end of the PSN operationally associated with the host computer and the plurality of end user devices, respectively. The PADS generate and respond to at least three formats of SDLC commands and responses, and, in association with their respective SDLC devices, perform at least four functions including a call setup phase, a data transfer phase, a call clearing phase, and handling of abnormal conditions. PAD means comprises qualified logical link control (QLLC) PAD means located at an end of said packet switching network for either operational association with said host computer or operational association with said plurality of end user devices.

US Patent:

RE373818, Sep 18, 2001

Filed:

Sep 6, 1995

Appl. No.:

8/673408

Inventors:

Robert H. Purcell - Boyds MD
John R. Ticehurst - Kensington MD
Jeffrey I. Cohen - Silver Spring MD
Suzanne U. Emerson - Rockville MD
Stephen M. Feinstone - Washington DC
Richard J. Daemer - Kensington MD
Ian D. Gust - Ivanhoe, AU

Assignee:

The United States of America as represented by the Department of Health and
Human Services - Washington DC

International Classification:

A61K 3929
C12N 708
C07H 2104

US Classification:

4242261

Abstract:

The present invention provides an attenuated hepatitis A virus useful as a vaccine.

US Patent:

48942286, Jan 16, 1990

Filed:

Jul 12, 1988

Appl. No.:

7/217824

Inventors:

Robert H. Purcell - Boyds MD
John R. Ticehurst - Kensington MD
Jeffrey I. Cohen - Newton MA
Suzanne U. Emerson - Silver Springs MD
Stephan M. Feinstone - Washington DC
Richard J. Daemer - Washington DC
Ian D. Gust - Melbourne, AU

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 3929

US Classification:

424 89

Abstract:

The present invention provides an attenuated hepatitis A virus useful as a vaccine.

US Patent:

20200190168, Jun 18, 2020

Filed:

Apr 25, 2018

Appl. No.:

16/608386

Inventors:

- Bethesda MD, US
Michael Gordon JOYCE - Washington DC, US
Jeffrey I. COHEN - Silver Spring MD, US

International Classification:

C07K 16/08
C07K 14/05

Abstract:

Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and to methods of using those compositions of matter for the same. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.

US Patent:

20190244255, Aug 8, 2019

Filed:

Feb 4, 2019

Appl. No.:

16/266298

Inventors:

Jeffrey Ronald COHEN - Washington DC, US

International Classification:

G06Q 30/02

Abstract:

A system includes a platform that allows consumers to access content from a content provider as desired. The consumer pays a transaction fee to access the content, and is not tied to any subscription based service. The consumer may receive the content directly from the content provider. Advertisers can bid upon access to deliver content to users. The advertisers bid to underwrite delivery of the content. The platform also allows advertisers to purchase additional delivery of the content using real-time data from the platform. Real-time information is provided to content providers and other entities as the content is accessed.